Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 03-2024 | 12-2023 | 09-2023 | 06-2023 | 03-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,158,820 | 1,960,841 | 2,194,552 | 2,309,574 | 3,948,122 |
| Marketable Securities | 104,114 | 197,506 | 108,716 | 381,272 | 149,288 |
| Receivables | 4,813,509 | 5,052,937 | 5,437,655 | 6,026,011 | 5,044,528 |
| Inventories | 8,348,096 | 7,953,552 | 7,975,476 | 7,908,630 | 7,299,782 |
| Other current assets | 1,229,661 | 1,351,204 | 1,271,861 | 1,420,233 | 1,303,160 |
| TOTAL | $17,654,200 | $16,516,040 | $16,988,260 | $18,045,720 | $17,744,880 |
| Non-Current Assets | |||||
| PPE Net | 13,729,460 | 12,522,190 | 13,069,540 | 13,105,800 | 12,515,090 |
| Investments And Advances | 2,971,195 | 2,535,842 | 2,872,912 | 2,872,762 | 2,803,542 |
| Intangibles | 66,824,770 | 62,616,500 | 66,953,730 | 70,782,350 | 67,046,810 |
| Other Non-Current Assets | 3,071,045 | 2,525,458 | 2,731,588 | 3,180,358 | 3,177,038 |
| TOTAL | $86,596,470 | $80,199,990 | $85,627,770 | $89,941,270 | $85,542,480 |
| Total Assets | $104,250,700 | $96,716,040 | $102,616,000 | $107,987,000 | $103,287,400 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 2,534,032 | 2,517,986 | 1,896,403 | 3,043,078 | 2,513,040 |
| Accounts payable and accrued liabilities | 3,777,895 | 3,288,929 | 2,905,438 | 3,218,745 | 4,804,324 |
| Other current liabilities | 8,890,132 | 8,947,195 | 10,636,210 | 10,228,770 | 9,329,401 |
| TOTAL | $15,960,410 | $15,518,740 | $16,336,560 | $18,262,710 | $18,366,360 |
| Non-Current Liabilities | |||||
| Long Term Debt | 30,887,860 | 29,198,330 | 30,390,110 | 31,610,850 | 29,916,280 |
| Other Non-Current Liabilities | 6,426,544 | 5,244,350 | 5,520,722 | 5,617,452 | 5,977,545 |
| TOTAL | $38,099,630 | $35,347,570 | $37,489,400 | $39,196,090 | $37,896,430 |
| Total Liabilities | $54,060,040 | $50,866,310 | $53,825,960 | $57,458,800 | $56,262,780 |
| Shareholders' Equity | |||||
| Common Shares | 11,568,510 | 11,400,490 | 11,567,870 | 12,237,800 | 12,404,950 |
| Retained earnings | 9,599,301 | 9,498,498 | 9,977,524 | 10,877,710 | 11,404,480 |
| Other shareholders' equity | 17,319,659 | 13,534,802 | 15,792,026 | 15,428,530 | 11,163,800 |
| TOTAL | $50,190,630 | $45,849,730 | $48,790,070 | $50,528,180 | $47,024,570 |
| Total Liabilities And Equity | $104,250,670 | $96,716,040 | $102,616,030 | $107,986,980 | $103,287,350 |